✦ LIBER ✦

Primary chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil in operable breast carcinoma

✍ Scribed by Catalina Falo; Abelardo Moreno; Enrique Benito; Belen Lloveras; Mar Varela; Jose Ma Serra; Luis Prieto; Diego Azpeitia; Agustin Escobedo

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 162 KB
Volume: 103
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.20829

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized trial comparing cyclophospham

Randomized trial comparing cyclophosphamide, methotrexate, and 5–fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma

✍ Giorgio Cocconi; Beatrice Di Blasio; Corrado Boni; Giancarlo Bisagni; Guido Ceci 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

## Abstract ## BACKGROUND According to the overview of Early Breast Cancer Trialists' Collaborative Group, anthracycline containing regimens are superior to cyclophosphamide, methotrexate, and 5–fluorouracil (CMF) as adjuvant chemotherapy for breast carcinoma, but no comparative information is ava

Low dose chemotherapy of metastatic brea

Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin

✍ Richard H. Creech; Robert B. Catalano; David T. Harris; Paul F. Engstrom; Paul J 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 647 KB

Comparison of 5-fluorouracil with 5-fluo

Comparison of 5-fluorouracil with 5-fluorouracil, cyclophosphamide, and methotrexate in metastatic colorectal carcinoma

✍ Frederick Richards II; Thomas L. Pajak; Miles R. Cooper; Charles L. Spurr 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 289 KB 👁 1 views

Thirty-eight patients with metastatic colorecal carcinoma were treated with 5-fluorouracil (5-FU), and 38 patients were treated with the combination of 5-FU, cyclophosphamide, and methotrexate. In terms of percent response, response duration, and survival there was no apparent difference between the

Combination chemotherapy for metastatic

Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate

✍ Ambrose Aboud; Aman U. Buzdar; Hwee-Yong Yap; Gabriel N. Hortobagyi; George R. B 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB

Twenty-nine patients with metastatic breast cancer were treated with fluorouracil, adriamycin, cyclophosphamide (FAC), and methotrexate (MTX), with or without leukovorin rescue. Of 24 evaluable patients, one achieved a complete remission and 17 had partial responses. The overall objective response r

Concurrent cyclophosphamide, methotrexat

Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma : A well tolerated adjuvant regimen

✍ Neil Isaac; Tony Panzarella; Anthea Lau; Catherine Mayers; Peter Kirkbride; Ian 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

## Background: The current study was conducted to assess the toxicity of concurrent adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (cmf) chemotherapy and radiotherapy (rt) for early breast carcinoma. ## Methods: In the current study, the authors reviewed the records of 680 consecutiv

Adriamycin, dibromodulcitol, and mitomyc

Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone

✍ Kavitha Pinnamaneni; Hwee-Yong Yap; Aman U. Buzdar; Alfred Distefano; George R. 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 351 KB 👁 2 views